Jérémie Richard

University of Ottawa

2 papers in the library · publishing 2026

Papers

Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions

International Journal of Eating Disorders July 2, 2026 Elena Koning, Jérémie Richard, Aaron Keshen

Psilocybin treatment shows promise as a transdiagnostic intervention for eating disorders and their common psychiatric comorbidities. Preliminary clinical evidence supports its feasibility, safety, and therapeutic effects, with robust transdiagnostic effects observed across comorbid conditions. Proposed mechanisms include serotonergic receptor agonism, psychoplastogenic effects, and neural network desynchronization that target shared vulnerabilities. These vulnerabilities map onto dimensional constructs in the Hierarchical Taxonomy of Psychopathology (Emotional Dysfunction superspectrum, Internalizing spectrum) and Research Domain Criteria (negative/positive valence, cognitive, and social process domains). Future research should explore pragmatic trial designs and dimensional outcome measures to capture real-world complexities.

DOI: 10.1002/eat.70164 Psilocybin Psychopathology Research domain criteria Comorbidity +12

Altered States, Enhanced Potential: Psychedelics and Physical Performance

June 12, 2026 Zane Qarni, Jérémie Richard preprint

People who use psychedelics like psilocybin mushrooms and LSD often describe them as enhancing physical performance indirectly by altering attention, increasing mind-body connection, promoting flow-like absorption, and reducing pain or fatigue. Some users report greater perceived strength, speed, endurance, coordination, or overall capability, along with effortless movement, reduced self-consciousness, sharper perception, and improved focus. Reports are predominantly positive or mixed, but concerns include overexertion, injury risk, impaired judgment, and fairness in competitive settings. Psychedelics may function more as potential-enhancing substances that change the subjective conditions of performance rather than as traditional performance-enhancing drugs. Whether perceived gains correspond to measurable improvement remains unclear.

DOI: 10.31234/osf.io/txgq2_v2 Psilocybin Perception Cognition Empirical research +10